Stay Informed. Stay Competitive. Get Free Email Updates Dow 30 & Emerging Growth

Stay Informed. Stay Competitive.

Get Free Updates

Dow 30 & Emerging Growth

AstraZeneca & Merck LYNPARZA®Receives Three New Advanced Cancer Approvals In Japan

By John F. Heerdink, Jr.

As per reports, AstraZeneca and Merck’s (MRK) LYNPARZA has been approved in Japan for the treatment of three types of advanced cancer: ovarian, prostate, and pancreatic cancer. The approvals authorize LYNPARZA for use as maintenance treatment after first-line chemotherapy for the above cancers. The parallel approvals by the Japanese Ministry of Health, Labor, and Welfare are based on results from the PAOLA-1, PROfound, and POLO Phase 3 trials, which each were published in The New England Journal of Medicine.

Dave Fredrickson, executive vice president, oncology business unit, AstraZeneca, stated, “These three approvals allow patients in Japan to be treated with LYNPARZA, a targeted treatment personalized to their specific biomarkers. They further underline the critical importance of biomarker testing at diagnosis, which helps physicians determine a course of treatment tailored to their individual patients to substantially delay disease progression.”

Merck & Co., Inc.  (MRK) is a global healthcare solutions provider that has been working towards bringing forward medicine and vaccines for some of the world’s most challenging diseases for more than a century.  They are committed to increasing health care access and continue to be at the leading edge of research. Merck has the industry’s largest immuno-oncology clinical research program. To learn more about Merck (MRK) and to track its ongoing progress please visit the Vista Partners Merck Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.


Post View Count : 417
(Read Original Story: LYNPARZA® (olaparib) Receives Three New Approvals in Japan in Business Wire)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us